Cardlytics' (CDLX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Cardlytics (NASDAQ:CDLX - Free Report) in a research report sent to investors on Thursday,Benzinga reports.

CDLX has been the topic of several other reports. Lake Street Capital lowered shares of Cardlytics from a "buy" rating to a "hold" rating and lowered their price target for the company from $18.00 to $5.00 in a report on Thursday, August 8th. Northland Capmk cut Cardlytics from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 16th. Northland Securities cut shares of Cardlytics from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $7.00 to $5.00 in a research note on Friday, August 16th. Evercore ISI started coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an "in-line" rating and a $4.00 price target on the stock. Finally, Craig Hallum cut shares of Cardlytics from a "buy" rating to a "hold" rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $6.92.

Cardlytics Stock Down 22.3 %

CDLX stock traded down $1.16 on Thursday, hitting $4.05. 2,897,122 shares of the company's stock were exchanged, compared to its average volume of 1,238,362. The firm has a 50 day moving average price of $3.68 and a two-hundred day moving average price of $6.78. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. Cardlytics has a 12-month low of $2.89 and a 12-month high of $20.52.

Cardlytics (NASDAQ:CDLX - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The firm had revenue of $69.64 million during the quarter, compared to the consensus estimate of $75.39 million. During the same quarter in the previous year, the company posted ($0.57) earnings per share. The company's revenue was down 9.2% compared to the same quarter last year. Analysts forecast that Cardlytics will post -1.72 EPS for the current year.

Insider Activity at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares of the company's stock, valued at $687,298.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the business's stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares of the company's stock, valued at $687,298.15. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Scott A. Hill purchased 40,000 shares of the stock in a transaction dated Monday, August 12th. The shares were purchased at an average price of $3.58 per share, with a total value of $143,200.00. Following the completion of the transaction, the director now owns 40,000 shares of the company's stock, valued at approximately $143,200. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 43,573 shares of company stock worth $151,612. Company insiders own 4.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Canton Hathaway LLC increased its position in shares of Cardlytics by 95.7% during the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company's stock worth $37,000 after acquiring an additional 2,200 shares during the period. SG Americas Securities LLC purchased a new position in shares of Cardlytics during the third quarter worth about $45,000. Creative Planning grew its position in Cardlytics by 35.4% in the 3rd quarter. Creative Planning now owns 29,537 shares of the company's stock valued at $95,000 after buying an additional 7,721 shares during the last quarter. XTX Topco Ltd purchased a new position in Cardlytics during the second quarter worth about $107,000. Finally, Quest Partners LLC lifted its holdings in shares of Cardlytics by 160.4% in the 2nd quarter. Quest Partners LLC now owns 17,956 shares of the company's stock valued at $147,000 after buying an additional 11,061 shares during the period. Hedge funds and other institutional investors own 68.10% of the company's stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.